SS/NEisSlc |
both kidneys wet weight to body weight ratio |
controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then tolvaptan (0.05 %) (for 49 days) |
Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. |
kidney mass |
male |
126 days
| 8 |
|
4.55 |
g/kg |
0.06 |
0.17 |
post excision weight measurement |
0.0 |
0 |
102324 |
2684 |
SS/NEisSlc |
systolic blood pressure |
controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then tolvaptan (0.05 %) (for 49 days) |
Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. |
arterial blood pressure trait |
male |
126 days
| 8 |
undefined |
235.0 |
mmHg |
13.0 |
36.77 |
tail cuff plethysmography |
0.0 |
0 |
102315 |
2684 |
SS/NEisSlc |
heart left ventricle end-diastolic diameter |
controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then tolvaptan (0.05 %) (for 49 days) |
Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. |
heart left ventricle end-diastolic diameter |
male |
126 days
| 8 |
|
7.0 |
mm |
0.2 |
0.57 |
transthoracic echocardiography |
0.0 |
0 |
102321 |
2684 |
SS/NEisSlc |
serum urea nitrogen level |
controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then tolvaptan (0.05 %) (for 49 days) |
Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. |
blood urea nitrogen amount |
male |
126 days
| 8 |
|
18.3 |
mg/dl |
1.2 |
3.39 |
serum urea nitrogen analysis |
0.0 |
0 |
102330 |
2684 |
SS/NEisSlc |
timed urine volume |
controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then tolvaptan (0.05 %) (for 49 days) |
Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. |
urine output |
male |
126 days
| 8 |
|
83.3 |
ml/d |
7.9 |
22.34 |
urine volume measurement method |
0.0 |
0 |
102336 |
2684 |
SS/NEisSlc |
urine total protein excretion rate |
controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then tolvaptan (0.05 %) (for 49 days) |
Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. |
total urine protein amount |
male |
126 days
| 8 |
|
124.0 |
mg/d |
21.0 |
59.4 |
urine protein analysis |
0.0 |
0 |
102339 |
2684 |
SS/NEisSlc |
body weight |
controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then tolvaptan (0.05 %) (for 49 days) |
Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. |
body mass |
male |
126 days
| 8 |
|
386.0 |
g |
6.0 |
16.97 |
body weighing method |
0.0 |
0 |
102312 |
2684 |
SS/NEisSlc |
heart left ventricle fractional shortening |
controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then tolvaptan (0.05 %) (for 49 days) |
Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. |
heart left ventricle end-diastolic diameter |
male |
126 days
| 8 |
|
44.3 |
% |
1.0 |
2.83 |
transthoracic echocardiography |
0.0 |
0 |
102318 |
2684 |
SS/NEisSlc |
serum creatinine level |
controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then tolvaptan (0.05 %) (for 49 days) |
Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. |
blood creatinine amount |
male |
126 days
| 8 |
|
0.35 |
mg/dl |
0.01 |
0.03 |
serum creatinine analysis |
0.0 |
0 |
102327 |
2684 |
SS/NEisSlc |
creatinine clearance |
controlled sodium content diet (0.3 %) (for 42 days) then controlled sodium content diet (8 %) (for 77 days) then tolvaptan (0.05 %) (for 49 days) |
Ishikawa M, et al., Int Heart J. 2013;54(2):98-106. |
glomerular filtration trait |
male |
126 days
| 8 |
|
3.6 |
ml/min |
0.7 |
1.98 |
serum creatinine analysis |
0.0 |
0 |
102333 |
2684 |